FrancophonIA/ELRC3.0 huggingface dataset:
English: Each pack contains 1 glass vial in a lead cannister placed in a plastic jar.
Croatian: Svako pakiranje sastoji se od 1 staklene bočice u olovnom spremniku koji se nalazi u plastičnoj posudi.
English: When in doubt, it is important to consult your nuclear medicine doctor.
Croatian: Ako niste sigurni, važno je savjetovati se sa svojim liječnikom nuklearne medicine.
English: • Tumour lysis syndrome (rapid breakdown of tumour cells)
Croatian: − karcinoidna kriza − sindrom lize tumora (brzo razaranje tumorskih stanica)
English: The product should be aseptically withdrawn through the stopper using sterilized single use needle and syringe after disinfection of the stopper.
Croatian: Proizvod se nakon dezinfekcije čepa mora aseptički izvući kroz čep upotrebom sterilizirane igle i štrcaljke za jednokratnu uporabu.
English: Lutetium (177Lu) has a half-life of 6.647 days.
Croatian: Lutecij (177Lu) ima vrijeme poluraspada od 6 647 dana.
English: Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials.
Croatian: Čuvanje radiofarmaceutika bit će u skladu s nacionalnim propisom o radioaktivnim materijalima.
English: Lu)-labeled conjugates in order to form a complex with free Lutetium (
Croatian: Trudnoća Lijekovi radioaktivno označeni lutecijem (
English: Due to the capacity of the chelating ligands (DTPA, EDTA) of forming water soluble complexes, the complexes and bound Lutetium(177Lu) are rapidly eliminated by the kidneys.
Croatian: Zbog sposobnosti tvorbe kompleksa topljivih u vodi s pomoću kelacijskih liganda (DTPA, EDTA) ovi se kompleksi i vezani lutecij (177Lu) brzo eliminiraju putem bubrega.
English: Radiation protection precautions in accordance with national regulations must therefore be taken.
Croatian: Nužno je poduzeti mjere zaštite od zračenja u skladu s nacionalnim propisima.
English: For instructions on extemporary preparation of the medicinal product before administration, see section 12.
Croatian: Za upute o neposrednoj pripremi lijeka prije primjene vidjeti dio 12.
English: The presence of free Lutetium (177Lu) chloride in the body after an inadvertent administration of Lumark will lead to increased bone marrow toxicity and haematopoetic stem cell damage.
Croatian: Prisutnost slobodnog lutecijeva (177Lu) klorida u tijelu nakon nehotične primjene lijeka Lumark dovest će povećane toksičnosti u koštanoj srži i oštećenja krvotvornih matičnih stanica.
English: For this reason it is mandatory to use protective high quality (latex/nitrile) gloves in any direct contact with the radiopharmaceutical (vial/syringe) and with the patient.
Croatian: (od lateksa/nitrila) u svakom izravnom dodiru s radiofarmaceutikom (bočica/štrcaljka) i bolesnikom.
English: Lumark is intended for in vitro radiolabelling of medicinal products, which are subsequently administered by the approved route.
Croatian: Način primjene Lumark je namijenjen za in vitro radioaktivno označavanje lijekova koji se naknadno primjenjuju odobrenim putem.
English: There have been reports of carcinoid crisis and other syndromes associated with release of hormones from functional neuroendocrine tumours following 177Lu peptide receptor radionuclide therapy, which may be related to irradiation of tumour cells.
Croatian: Zabilježeni su slučajevi karcinoidne krize i drugih sindroma povezanih s oslobađanjem hormona iz funkcionalnih neuroendokrinih tumora nakon peptidne radionuklidne terapije lutecijem (177Lu), što je možda povezano sa zračenjem tumorskih stanica.
English: Adrenals Brain
Croatian: Nadbubrežne žlijezde Mozak
English: The use of Lutetium (177Lu)-labelled medicines does involve exposure to small amounts of radioactivity.
Croatian: Uporaba lijekova označenih lutecijem (177Lu) uključuje izlaganje malim količinama radioaktivnosti.
English: Lumark is only used to radiolabel medicines that have been specifically developed for use with the active substance lutetium (177Lu)chloride.
Croatian: Lumark se upotrebljava samo za radioaktivno označavanje lijekova koji su posebno osmišljeni za uporabu s djelatnom tvari lutecijevim (177Lu) kloridom.
English: Administration of the medicine radiolabelled with Lumark and conduct of the procedure Lumark must be used only in combination with another medicine which has been specifically developed and authorised for being combined with Lumark.
Croatian: Lumark se smije upotrebljavati samo u kombinaciji s drugim lijekom koji je posebno razvijen i odobren za kombiniranje s Lumarkom.
English: A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturer(s) responsible for batch release
Croatian: PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE LIJEKA U PROMET Naziv i adresa proizvođača odgovornog za puštanje serije lijeka u promet
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER I.D.B.
Croatian: 11. IME I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET I.D.B Holland B.V.
English: For instruction on extemporary preparation of the medicinal product before administration, see section 12.
Croatian: Za uputu o neposrednoj pripremi lijeka prije primjene vidjeti dio 12.
English: EXPIRY DATE Expiry date: {DD/MM/YYYY} hh:mm CET
Croatian: ROK VALJANOSTI Rok valjanosti: {DD/MM/GGGG} ss:mm CET
English: LIST OF EXCIPIENTS Hydrochloric acid Water for injections
Croatian: Kloridna kiselina Voda za injekcije
English: (GBq: GigaBecquerel is the unit in which radioactivity is measured).
Croatian: Vrijeme umjeravanja aktivnosti definirano je kao kraj proizvodnje. (GBq: Gigabekerel je jedinica kojom se mjeri radioaktivnost).
English: How to use the medicine radiolabelled with Lumark
Croatian: Kako koristiti lijek koji je radioaktivno označen Lumarkom
English: Absorbed dose per unit activity administered for various tissues
Croatian: Tablica 1.: Apsorbirana doza po primijenjenoj jedinici aktivnosti za različita tkiva Podaci prema ICRP-30
English: Treatment with Lutetium (177Lu) radioligand therapy may lead to the following side effects
Croatian: Liječenje radioligandnom terapijom lutecijem (177Lu) može dovesti do sljedećih nuspojava:
English: The possible use of chelating therapies could interfere with the use of Lutetium(177Lu)-labeled medicinal products.
Croatian: Moguća primjena kelirajućih lijekova može ometati primjenu lijekova označenih lutecijem (177Lu).
English: For administration after in vitro radiolabelling.
Croatian: NAČIN PRIMJENE LIJEKA Za primjenu nakon radioaktivnog označavanja in vitro.
English: Marketing Authorisation Holder I.D.B.
Croatian: Nositelj odobrenja za stavljanje lijeka u promet I.D.B Holland B.V.
English: Subsequently, the marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
Croatian: popis) predviđenim člankom 107.c stavkom 7. Direktive 2001/83/EZ i objavljenim na europskom internetskom portalu za lijekove.
English: Radiopharmaceuticals should be received, used and administered only by authorised persons in designated clinical settings.
Croatian: Radiofarmaceutike smiju zaprimati, upotrebljavati i bolesnicima davati samo ovlaštene osobe u za to određenim kliničkim uvjetima.
English: EU/1/15/1013/001 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Croatian: DATUM PRVOG ODOBRENJA/DATUM OBNOVE ODOBRENJA
English: These chelating agents help with the elimination of Lutetium (177Lu) radiotoxicity by an exchange between the calcium ion in the complex and the Lutetium (177Lu) ion.
Croatian: Navedeni kelirajući agensi pomažu pri eliminaciji radioaktivne toksičnosti lutecija (177Lu) izmjenom kalcijeva iona u kompleksu s lutecijevim (177Lu) ionom.
English: The radiation dose received by the various organs following administration of a Lutetium (177Lu)-labelled medicinal product will be dependent on the specific molecule being radiolabelled.
Croatian: Doza zračenja koju prime različiti organi nakon primjene lijeka označenog lutecijem (177Lu) ovisit će o konkretnoj molekuli koja se radiaktivno označava.
English: Grounds for the variation to the terms of the marketing authorisation(s) On the basis of the scientific conclusions for Lutetium (177Lu) chloride the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing Lutetium (177Lu) chloride is unchanged subject to the proposed changes to the product information.
Croatian: Na temelju znanstvenih zaključaka za lutecijev (177Lu) klorid, CHMP smatra da je omjer koristi i rizika lijeka(ova) koji sadrži(e) lutecijev (177Lu) klorid nepromijenjen, uz predložene izmjene informacija o lijeku.
English: What Lumark looks like and contents of the pack Lumark is presented as a sterile, clear, and colourless solution in a colourless type I glass vial of 10 mL, closed with a bromobutylrubber stopper and aluminium overseal
Croatian: Lumark je sterilna, prozirna i bezbojna otopina u bezbojnoj staklenoj bočici tipa
English: It contains the active substance Lutetium (177Lu) chloride.
Croatian: Sadrži djelatnu tvar lutecijev (177Lu) klorid.
English: Only syringe needles (for example non-metallic) with proven resistance to dilute acid should be used to minimize trace metal impurity levels.
Croatian: Kako bi se smanjila razina metalnih onečišćenja u tragovima, treba upotrebljavati samo igle za štrcaljke (primjerice nemetalne) koje su dokazano otporne na razrijeđenu kiselinu.
English: Gallbladder Wall LLI Wall Small Intestine Stomach Wall ULI Wall Heart Wall Kidneys
Croatian: Stijenka donjeg dijela debelog crijeva Tanko crijevo
English: Lumark is a radiopharmaceutical precursor.
Croatian: 4.1 Terapijske indikacije Lumark je radiofarmaceutski prekursor.
English: Each vial contains a volume varying from 0.1 to 5 mL corresponding to an activity ranging from 8 to 400 GBq (at ART).
Croatian: Svaka bočica sadrži volumen od 0,1 do 5 ml, što odgovara aktivnosti između 8 i 400 GBq (pri ART-u).
English: The quantity of Lumark required for radiolabelling and the quantity of the product to be radiolabelled with Lutetium(177Lu) that is subsequently administered will depend on the medicinal product to be radiolabelled and its intended use.
Croatian: Količina lijeka Lumark potrebna za radioaktivno označavanje i količina lijeka koji treba biti označen lutecijem (177Lu), a koji se naknadno primjenjuje, ovisi o lijeku koji se radioaktivno označava i o njegovoj namjeni.
English: NAME OF THE MEDICINAL PRODUCT Lumark 80 GBq/mL radiopharmaceutical precursor, solution
Croatian: NAZIV LIJEKA Lumark 80 GBq/ml radiofarmaceutski prekursor, otopina
English: Information on radiation dosimetry of each different medicinal product following administration of the radiolabelled preparation will be available in the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled.
Croatian: Informacije o radijacijskoj dozimetriji svakog pojedinog lijeka nakon primjene radioaktivno označenog pripravka navedene su u Sažetku opisa svojstava lijeka / uputi priloženoj uz lijek koji se radioaktivno označava.
English: • Mild temporary hair loss Common (may affect up to 1 in 10 people):
Croatian: − rak koštane srži (mijelodisplastični sindrom) Manje često (mogu se javiti u do 1 na 100 osoba):
English: Radioactive medicinal products should be received, used and administered only by authorised persons in designated clinical settings.
Croatian: Radioaktivne lijekove smiju zaprimati, koristiti i bolesnicima davati samo ovlaštene osobe u za to određenim kliničkim uvjetima.
English: A more detailed study of the biodistribution of Lutetium (177Lu) chloride in mice confirms the relatively high uptake in the liver, kidneys and bone marrow The results indicated that lutetium (177Lu) chloride is accumulated in the bone marrow and emphasizes the importance of all Lutetium (177Lu) to be peptide-bound at injection, as well as the in-vivo stability of the radionuclide-chelate-complex during therapy.
Croatian: Rezultati ukazuju da se lutecijev (177Lu) klorid nakuplja u koštanoj srži te naglašavaju važnost da cjelokupni lutecij (177Lu) bude vezan za peptide u injekciji, kao i in vivo stabilnost kompleksa radionuklida i kelatora tijekom terapije.
English: In all cases, the risk of the radiation is outweighed by the potential benefit of receiving the radiolabelled medicine.
Croatian: U svakom slučaju, potencijalna korist primanja radioaktivno označenog lijeka nadilazi rizik od zračenja.
English: Each vial contains a volume varying from 0.1 to 5 mL corresponding to an activity ranging from 8 to 400 GBq at the ART.
Croatian: Svaka bočica sadržava volumen od 0,1 do 5 ml, što odgovara aktivnosti između 8 i 400 GBq pri ART-u.
English: Please refer to the package leaflet of the medicine that is to be radiolabelled with Lumark.
Croatian: Pogledajte uputu o lijeku koji će biti radioaktivno označen Lumarkom.
English: For more information, refer to the package leaflet of the particular medicine to be radiolabelled.
Croatian: Za više informacija pogledajte uputu o određenom lijeku koji će biti radioaktivno označen.
English: Storage of radiopharmaceuticals should be in accordance with national regulations for radioactive materials.
Croatian: Radiofarmaceutike je potrebno čuvati u skladu s nacionalnim propisima za radioaktivne materijale.
English: Such information is supplied in the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Croatian: Takve su informacije navedene u Sažetku opisa svojstava lijeka/uputi priloženoj uz lijek koji se radioaktivno označava.
English: Bone marrow cancer (myelodysplastic syndrome and acute myeloid leukaemia) has been reported in patients several years after treatment with Lutetium (177Lu) peptide receptor radionuclide therapy for neuroendocrine tumours.
Croatian: Rak koštane srži (mijelodisplastični sindrom i akutna mijeloična leukemija) prijavljen je u bolesnika nekoliko godina nakon peptidne radionuklidne terapije lutecijem (177Lu) kod liječenja neuroendokrinih tumora.
English: The radiopharmaceutical precursor solution is packaged in colourless type I glass vial of 10 mL, closed with a bromobutylrubber stopper and aluminium overseal.
Croatian: I od 10 ml koja je zatvorena čepom od bromobutilne gume i aluminijskim zaštitnim zatvaračem.
English: Hepatotoxicity:
Croatian: Hepatotoksičnost
English: Storage must be in accordance with local regulations for radioactive substances 10.
Croatian: Potrebno je čuvati u skladu s lokalnim propisima za radioaktivne tvari.
English: Pregnancy The use of Lutetium (177Lu)-labelled medicinal products is contraindicated during established or suspected pregnancy or when pregnancy has not been excluded (see section 4.3).
Croatian: Lu) kontraindicirani su u slučaju ustanovljene trudnoće, kada se sumnja na trudnoću ili kada trudnoća nije isključena (vidjeti dio 4.3).
English: What Lumark contains - The active substance is Lutetium (177Lu) chloride.
Croatian: Sadržaj pakiranja i druge informacije Što Lumark sadrži - Djelatna tvar jest lutecijev (177Lu) klorid.
English: One mL of solution contains 80 GBq Lutetium (177Lu) chloride at activity reference time (ART), corresponding to at most a maximum of 160 microgram of Lutetium.
Croatian: Jedan ml otopine sadrži 80 GBq lutecijeva (177Lu) klorida pri vremenu umjeravanja aktivnosti (ART), što odgovara najviše 160 mikrograma lutecija.
English: Lumark 80 GBq/mL radiopharmaceutical precursor, solution Lutetium (177Lu) chloride
Croatian: Lumark 80 GBq/ml radiofarmaceutski prekursor, otopina lutecijev (177Lu) klorid
English: Cases of hepatotoxicity have been reported in the post-marketing setting and in the literature in patients with liver metastases undergoing treatment with 177Lu peptide receptor radionuclide therapy for neuroendocrine tumours.
Croatian: Nakon stavljanja lijeka u promet i u literaturi zabilježeni su slučajevi hepatotoksičnosti u bolesnika s metastazama u jetri liječenima peptidnom radionuklidnom terapijom lutecijem (177Lu) zbog neuroendokrinih tumora.
English: Email: quality@idb-radiopharmacy.com
Croatian: Faks: +31(0)13 5079 912 e-pošta: quality@idb-radiopharmacy.com
English: Liver
Croatian: BOČICA
English: pregnancy should be excluded using an adequate/validated test.
Croatian: Prije korištenja lijekova označenih lutecijem (177Lu) valja isključiti mogućnost trudnoće pomoću prikladnog/validiranog testa.
English: If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.
Croatian: (RMP), dokumenti mogu biti podneseni istodobno.
English: If you are pregnant Medicines radiolabelled with Lumark must not be administered if you are pregnant.
Croatian: Ako ste trudni, ne smijete primati lijekove koji su radioaktivno označeni Lumarkom.
English: • Reduction in blood cell counts (platelets, red or white blood cells)
Croatian: Vrlo česte nuspojave (mogu se javiti u više od 1 na 10 osoba): - smanjenje broja krvnih stanica (krvnih pločica, crvenih ili bijelih krvnih stanica) - mučnina - povraćanje
English: Not known (frequency cannot be estimated from the available data):
Croatian: − rak koštane srži (akutna mijeloična leukemija) Nepoznato (učestalost se ne može procijeniti iz dostupnih podataka):
English: Lumark is used for radiolabelling medicines, a technique in which medicines are tagged (radiolabelled) with a radioactive form of the element lutetium, known as lutetium (177Lu).
Croatian: (radioaktivno označavaju) radioaktivnim oblikom elementa lutecija poznatog pod nazivom lutecij (177Lu).
English: If you get any side effects, talk to your nuclear medicine doctor.
Croatian: Ako imate ikakvih pitanja, obratite se svom liječniku nuklearne medicine.
English: Myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) have been observed after treatment with Lutetium (177 Lu) peptide receptor radionuclide therapy for neuroendocrine tumours (see section 4.8).
Croatian: Mijelodisplastični sindrom i akutna mijeloična leukemija Mijelodisplastični sindrom (MDS) i akutna mijeloična leukemija (AML) uočeni su nakon peptidne radionuklidne terapije lutecijem (177 Lu) (engl.
English: Effects on ability to drive or use machines following treatment by Lutetium (177Lu)-labelled medicinal products is specified in the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled.
Croatian: Informacije o utjecaju na sposobnost upravljanja vozilima i rada sa strojevima nakon liječenja lijekovima radioaktivno označenima lutecijem (177Lu) navedene su u Sažetku opisa svojstava lijeka/uputi priloženoj uz lijek koji se radioaktivno označava.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Lumark 80 GBq/mL radiopharmaceutical precursor, solution Lutetium (177Lu) chloride
Croatian: NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA Lumark 80 GBq/ml radiofarmaceutski prekursor, otopina lutecijev (177Lu) klorid
English: The following preparations must be available in medical institutions, which use Lumark for radiolabelling of carrier molecules for therapeutic purposes: - Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate) or - Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
Croatian: - Ca-DTPA (trinatrijev kalcijev dietilentriaminpentaacetat) ili - Ca-EDTA (kalcijev dinatrijev etilendiamintetraacetat)
English: Lumark is only to be used by specialists experienced with in vitro radiolabelling Posology
Croatian: 4.2 Doziranje i način primjene Lumark smiju koristiti samo specijalisti s iskustvom u radioaktivnom označavanju in vitro.
English: SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE Any unused product or waste material should be disposed of in accordance with local requirements.
Croatian: POSEBNE MJERE ZA ZBRINJAVANJE NEISKORIŠTENOG LIJEKA ILI OTPADNIH
English: Hormone release syndromes:
Croatian: Sindrom oslobađanja hormona
English: Individual benefit/risk justification
Croatian: 4.4 Posebna upozorenja i mjere opreza pri uporabi Procjena omjera koristi/rizika kod pojedinog bolesnika
English: What you need to know before the medicine radiolabelled with Lumark is used 3.
Croatian: Što morate znati prije nego počnete primati lijek koji je radioaktivno označen Lumarkom 3. Kako koristiti lijek koji je radioaktivno označen Lumarkom 4. Moguće nuspojave
English: By intravenous route, the LD50 in rats and mice ranges between 30 and 60 mg/kg.
Croatian: Kod intravenskog načina primjene u miševa i štakora LD50 iznosi između
English: No interaction studies of Lutetium (177Lu) with other medicinal products have been performed.
Croatian: 4.5 Interakcije s drugim lijekovima i drugi oblici interakcija Nisu provedena ispitivanja interakcije lutecija (177Lu) s drugim lijekovima.
English: Total Body
Croatian: Maternica Ukupno u tijelu
English: The dosimetry table below is presented in order to evaluate the contribution of non-conjugated Lutetium(177Lu) to the radiation dose following the administration of Lutetium (177Lu)-labelled medicinal product or resulting from an accidental intravenous injection of Lumark.
Croatian: radijacijskoj dozi nakon primjene lijeka označenog lutecijem (177Lu) ili kao rezultat nehotičnog intravenskog injiciranja lijeka Lumark.
English: Myelosuppression
Croatian: Ekstravazacija
English: Skin and subcutaneous tissue disorders: very common: Alopecia
Croatian: Vrlo često: alopecija
English: For more information concerning the paediatric use of Lutetium (177Lu)-labelled medicinal products refer to the Summary of Products Characteristics/package leaflet of the the particular medicinal product to be radiolabelled.
Croatian: Za više informacija o pedijatrijskoj primjeni lijekova koji se označavaju lutecijem (177Lu) pogledajte Sažetak opisa svojstava lijeka/uputu priloženu uz lijek koji se radioaktivno označava.
English: The pharmacokinetic properties of Lutetium (177Lu)-labelled medicinal products prepared by radiolabelling with Lumark, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
Croatian: Farmakokinetička svojstva lijekova radioaktivno označenih lutecijem (177Lu) primjenom lijeka Lumark prije davanja bolesniku ovise o prirodi lijeka koji se radioaktivno označava.
English: The pharmacodynamic properties of Lutetium (177Lu)-labelled medicinal products prepared by radiolabelling with Lumark, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
Croatian: Farmakodinamička svojstva lijekova radioaktivno označenih lutecijem (177Lu) primjenom lijeka Lumark prije davanja bolesniku ovise o prirodi lijeka koji se radioaktivno označava.
English: For information concerning special warnings and precautions for use of 177Lu-labelled medicinal products refer to the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Croatian: Za informacije o posebnim upozorenjima i mjerama predostrožnosti za primjenu lijekova koji se radioaktivno označavaju lutecijem (177Lu) pogledajte Sažetak opisa svojstava lijeka/uputu priloženu uz lijek koji se radioaktivno označava.
English: EXPIRY DATE EXP: {DD/MM/YYYY} BATCH NUMBER
Croatian: Rok valjanosti: {DD/MM/GGGG}
English: Extravasation: There have been reports of extravasation of Lutetium (177Lu) labelled ligands in the post-marketing setting.
Croatian: Nakon stavljanja lijeka u promet prijavljeni su slučajevi ekstravazacije liganada obilježenih lutecijem (177Lu).
English: Possible side effects
Croatian: NAVOĐENJE DJELATNE/IH
English: Urinary Bladder Wall Uterus
Croatian: Stijenka mokraćnog mjehura
English: Dry mouth has been reported among patients with metastatic castration resistant prostate cancer receiving PSMA-targeted Lutetium (177Lu)-labelled radioligands and has been transient.
Croatian: U bolesnika s karcinomom prostate koji su primali terapiju lutecijem (177Lu) zabilježna su suha usta, no to je bilo privremeno.
English: Dry mouth has been reported among patients with prostate cancer receiving treatment with Lutetium (177Lu)
Croatian: U bolesnika s metastatskim karcinomom prostate rezistentnim na kastraciju koji su primali lutecijem (177Lu)